Werewolf Therapeutics, Inc.
HOWL
$0.71
$0.0568.56%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.89M | 3.39M | 9.28M | 16.22M | 19.94M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.89M | 3.39M | 9.28M | 16.22M | 19.94M |
| Cost of Revenue | 53.09M | 47.49M | 45.80M | 40.11M | 38.91M |
| Gross Profit | -51.20M | -44.10M | -36.51M | -23.89M | -18.96M |
| SG&A Expenses | 22.39M | 22.11M | 21.82M | 21.56M | 21.54M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 75.48M | 69.59M | 67.62M | 61.66M | 60.45M |
| Operating Income | -73.59M | -66.21M | -58.34M | -45.44M | -40.50M |
| Income Before Tax | -70.52M | -62.12M | -53.73M | -41.58M | -37.37M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -70.52 | -62.12 | -53.73 | -41.58 | -37.37 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -70.52M | -62.12M | -53.73M | -41.58M | -37.37M |
| EBIT | -73.59M | -66.21M | -58.34M | -45.44M | -40.50M |
| EBITDA | -71.78M | -64.38M | -56.51M | -43.64M | -38.74M |
| EPS Basic | -1.63 | -1.50 | -1.35 | -1.09 | -1.05 |
| Normalized Basic EPS | -1.01 | -0.93 | -0.83 | -0.68 | -0.66 |
| EPS Diluted | -1.65 | -1.52 | -1.38 | -1.09 | -1.05 |
| Normalized Diluted EPS | -1.01 | -0.92 | -0.83 | -0.68 | -0.66 |
| Average Basic Shares Outstanding | 173.31M | 165.40M | 157.35M | 149.39M | 142.57M |
| Average Diluted Shares Outstanding | 173.83M | 165.93M | 157.87M | 149.39M | 142.57M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
